Clinical Trial Update: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide [Phase 4]

View source ↗

Summary

Phase 4 trial comparing patient experience on octreotide long-acting release versus lanreotide in neuroendocrine tumor patients; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• SOMATULINE DEPOT (LANREOTIDE ACETATE)
• Sandostatin LAR (octreotide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroendocrine Tumors | Phase 4 | Status: COMPLETED | Results posted: 2025-05-09